Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51

H Direskeneli

Behçet’s disease (BD) is a multisystemic disorder with mucocutaneous, ocular, arthritic, vascular, and central nervous system involvements.

Recent developments in the immunopathogenesis of BD are discussed in this review. Box 1 summarises the major aspects covered.

Neutrophil activation

Neutrophils are mature immune cells with a very short life in vitro and have a pivotal role in innate immune responses. As typical BD lesions such as pustular folliculitis, pathergy reactions, and hypopyon have significant neutrophil infiltrations, neutrophil functions and activation status have been extensively investigated.

Contradictions, neutrophil functions and activation status have been extensively investigated. Confrontations, neutrophil functions and activation status have been extensively investigated. Confrontations, neutrophil functions and activation status have been extensively investigated.

In a recent study, which showed decreased fMLP stimulated superoxide production in BD and patients with sepsis, consecutive restimulations of prestimulated BD neutrophils produced a smaller increase in superoxide production than in healthy controls, implying a state of in vivo neutrophil preactivation.

An in vivo “primed” state of neutrophils with a dual signalling system for activating neutrophil oxidase has been suggested previously. Agents such as fMLP or the cytokines, tumour necrosis factor α (TNFα) and granulocyte monocyte colony stimulating factor, have been shown to increase tyrosine phosphorylation of various intracellular proteins and to prime neutrophils in vivo without full activation, which might also be the case in BD with its proinflammatory cytokines. In HLA-B51 transgenic mice, a presumed model for BD, the only abnormality seen is increased superoxide release in response to fMLP. High superoxide responses were also present in HLA-B51+ patients and healthy controls in the same study, but this has not been confirmed.

Cellular and humoral immunity

T cell activation, both in the peripheral blood and tissue specimens, is present in BD. A possibly antigen driven change in the peripheral blood CD4+ and CD8+ T cell repertoire, with oligoclonal T cell receptor Vβ subset increases, has been observed. However, the high individual variability of dominant Vβ subsets between patients make it impossible to implicate a single antigen as driving the T cell activation. γδ+ T cells are also increased, both in the peripheral blood and tissue infiltrations, with high expressions of the early T cell activation markers CD29 and CD69.

As for most other autoimmune disorders and vasculitides, the Th1-type cytokine profile is predominant in BD. Both CD4+ and CD8+ T cells, which produce the Th1 type proinflammatory cytokines interleukin 2 (IL2) and interferon γ (IFNγ), are increased in the peripheral blood, and correlate with disease activity. IL12, which drives the Th1 response in naïve T cells, is raised in BD sera, in correlation with Th1 lymphocytes. Th2 lymphocytes and levels of Th2 cytokines are generally found to be low, except in a study in which there were high in vitro IL4, IL10, and IL13 levels. Peripheral γδ+ T cells also secrete IFNγ and TNFα as major cytokines, which is it is suggested are of the Th1 type.

Although BD does not have the features of a classical autoimmune disorder, such as female dominance, hyperimmunoglobulinaemia, Sjögren’s syndrome, and antinuclear antibodies, some B cell activity, such as increased spontaneous immunoglobulin secretion, is reported. Autoantibodies such as antiendothelial cell (AEC), antilymphocyte, and anticardiolipin antibodies, especially of IgA isotype, are also present. Although the total B cell number is

Box 1 Immunopathogenic aspects of Behçet’s disease

- Neutrophil activation
- Cellular and humoral immunity
- Antigenic stimuli
- Herpes simplex virus
- Streptococci and superantigens
- Heat shock proteins (65 kDa, αβ-crystallin)
- HLA-B51 and antigen presentation
- Retinal-S antigen and HLA-B51 as autoantigens
- Vascular disease and antiendothelial cell antibodies
- Sex aspects
normal, they express increased levels of activation markers such as CD13, CD33, CD80, and the memory marker CD45RO. The low level of CD5+CD19+ B cells which produce autoantibodies suggests that BD is distinct from classical autoantibody mediated disorders. However, as the current role of B cells in the immune system is not limited to antibody production, but also includes antigen presentation, the activated and memory type B cell profile might modulate T cell activation in BD.

**Antigenic stimuli**

**HERPES SIMPLEX VIRUS**

A viral cause for BD was first postulated by Behçet in 1937 and, later, viral particles were claimed to be isolated from patients’ fluids. Although herpetiform ulcers are not common, herpes simplex virus (HSV) is currently the only virus possibly associated with BD. Serum anti-HSV-1 antibodies are found in a higher proportion of patients with BD than in controls, and circulating immune complexes with the HSV-1 antigen have been reported. HSV DNA has been demonstrated in the genital and intestinal ulcers of patients with BD, but not in oral ulcers. Thirty per cent of ICR mice inoculated with HSV are reported to have Behçet’s disease-like symptoms, with genital herpetic lesions, such as erythema nodosum and mucocutaneous ulcers in BD.26–30

**STREPTOCOCCI AND SUPERANTIGENS**

As BD starts mostly from the oral mucosal surface (oral aphthae are the first manifestation in 70% of patients), oral microbial flora have long been implicated in the pathogenesis. Clinical observations such as increased oral manifestations after dental treatment, hypersensitivity to streptococcal skin tests, dominance of atypical streptococcal species in patients with the oral flora of BD, and recent reports of beneficial antibacterial treatment suggest a role for streptococcal involvement in BD. Streptococcus sanguis and Streptococcus salivarius subsp. salivarius have been isolated from BD lesions. These bacteria are able to secrete IL6, IL8, and TNFα, which might modulate T cell activation in BD.26

**HERPES SIMPLEX VIRUS**

**Heat shock proteins (HSP)**

Heat shock proteins, especially 60/65 kDa HSP (HSP65), are possible candidate antigens for BD. HSPs have scavenger roles for other intracellular proteins under denaturing stress conditions such as infections, hypoxia, trauma, and toxic drugs. Various immune mechanisms are described for the role of HSPs in infectious, autoimmune, and malign disorders. As significant sequence homology exists between the mammalian and microbial HSPs (mycobacterial and human HSP60/65 have over 50% homology), it has been suggested that bacterial HSPs might stimulate autoreactive T cells by cross reactivity mechanisms.

**HSP65** is expressed abundantly in epidermal regions of active skin lesions, such as erythema nodosum and mucocutaneous ulcers in BD.16 Lehner et al first suggested the concept of HSP65 as a pathogenic antigen in BD by identifying anti-HSP65 antibodies cross reactive with oral mucosal homogenates and oral streptococci.17 Four epitopes of mycobacterial HSP65 derived peptides and to their 50–80% homologues on human HSP60 were significantly higher in patients with BD from the UK, Japan, and Turkey than in controls.16–22 HSP peptide responsive T cells were mainly of the γδ T cell subset in the UK, whereas CD4+ T cells were dominant in Turkey and Japan.41–43 However, γδ T cells were also present in tissue specimens where HSP65 expression was up regulated, suggesting that the local HSP responsive T cell repertoire might be different from that of peripheral blood.44

Purified protein derivative and HSP65-specific long term T cell lines (mainly TCR αβ+CD4+ or CD8+) are also highly reactive to human HSP60 derived peptides in both patients with BD and healthy controls.22 Most purified protein derivative stimulated lines responded to epitope 425–41 of HSP60 in patients with BD (an epitope not described in primary cultures of patients with BD), whereas epitope 336–51 dominated in controls, suggesting that the patterns of response and the immunodominance of epitopes may differ in patients with BD from those of healthy controls.

When anti-HSP responses were compared with antibacterial responses (S sanguis and E coli) to investigate cross reactivity further, CD4+ T cell responses were mainly seen against HSP60 peptides, whereas CD11b+, CD4+CD56+ cytotoxic T cell responses were dominant against whole bacterial extracts. The increased presence of similar cytotoxic-suppressor CD4+CD16+ and CD4+CD56+ T cell subsets in the unstimulated peripheral blood T cell repertoire of patients with BD also implicates an in vivo bacterial prestimulation. Similarly to the T cell studies, “cross reactivity” is also demonstrated for anti-HSP60 antibodies. Both antistreptococcal and antiretinal HSP60 antibodies are raised in the serum samples of patients with BD and uveitis, with significant cross inhibition. Increased anti-HSP65 antibody responses are also present in
the cerebrospinal fluid (CSF) of patients with neuro-BD with parenchymal involvement.47 In an animal model of HSP subcutaneous inoculation in rats, human HSP derived, immunodominant peptides caused an experimental uveitis without other symptoms of BD.48 Oral administration of peptides also induced uveitis, causing an “oral triggering”, in contrast with most models of “oral tolerance”, where the mucosal immune encounter with pathogenic antigens suppresses immune activity.49 Heat shock to oral mucosa also increases S saugus colonisation and ocular inflammation in mice, suggesting that stress may be crucial for the breakdown of mucosal defences and anti-HSP reactivity.50

In some other experimental models, such as adjuvant arthritis, T cell responses to self HSP60 are protective.51 As the anti-inflammatory cytokines, IL4 and transforming growth factor β are released after in vitro human HSP60 stimulation, self HSP reactivity is also claimed to be immunosuppressive in juvenile and adult rheumatoid arthritis.32 However, stimulation with the human HSP60 peptide 336–51 produced IFNγ, TNFα, and IL12 in BD lymphocytes, whereas the Th2 cytokines IL4 and IL10 suppressed the proliferative responses.53 On the other hand, the only HSP65 stimulated, TCR δδ+, long term T cell line from a patient with BD secreted IL4 and had a Th2 profile (unpublished data), suggesting that both pathogenic and protective immune responses may be induced by HSPs.

With the available data, an immunological model for the possible role of HSP65 as a T cell antigen is outlined in fig 1. According to this model, human HSP60-reactive T cell clones, escaping high affinity clonal deletion, may be positively selected with low affinity in thymus where HSP60 is present as a self antigen and circulate in an anergic form (Th2 type?) in the peripheral blood. In oral mucosa and, possibly, in the skin, after non-specific minor injuries and oral ulcer development, streptococcal and human HSP60 expression may be up regulated, which stimulates self HSP60 reactive clones. These T cells might then pass to the ocular compartment (after non-specific anterior uveitis which breaks down the blood-retina barrier?), be further activated with retinal-HSP60, and may cause a chronic ocular inflammation with Th1 type cytokine activity.

Other heat shock proteins may also be antigenic in BD. αβ-Crystallin is a small stress protein, constitutively present in vertebrate eye lens, skeletal muscle, and kidney epithelial cells. Stress-induced expression of αβ-crystallin in glia cells of the central nervous system has been demonstrated.54 Serum and CSF IgG and serum IgM antibody responses to αβ-crystallin are raised in patients with neuro-BD compared with patients with non-inflammatory nervous system diseases.55 When responses were subclassified according to the type of neuro-BD, similar to the anti-HSP65 responses, patients with parenchymal neuro-BD had higher CSF IgG responses to αβ-crystallin than the neuro-BD group with intracranial hypertension (vascular disease). CSF IgG responses to HSP65 and αβ-crystallin also showed a significant correlation with each other, possibly owing to similar immune mechanisms driving both autoantibody responses in the CSF.

**Genetic predisposition and HLA-B51** Behçet’s disease has a strong genetic background with familial aggregation.56 Among various genetic markers, relationship to HLA class I antigens B5 and its subclass B51 is the most commonly reported,57 and linkage of the HLA-B locus in BD has also recently been shown.58 The presence of this marker has an odds ratio of 1.5 to 16 in different series.59 An

**Figure 1** Role of bacterial and human heat shock protein (HSP) 60/65 as T cell antigens in Behçet’s disease. APC = antigen presenting cells.
important question is whether B51 is a marker of susceptibility or severity in BD. Although a high prevalence is found in hospital based patients (50–80%), a field study from Turkey found B51 in only 26% of the cases. Most patients in this study had not been diagnosed as BD previously and had a clinically mild, mucocutaneous disease.

The role of HLA class I antigens such as B51 is the presentation of endogenous antigens synthesised within the cell to CD8+ cytotoxic-suppressor T cells. The antigen-specific region of B51 has been analysed, and 8–10 amino acid length sequences of possible, antigenic peptides were reported.62 Peptides derived from autoantigens, such as thymidylate synthase (aa 253–61), guanine-nucleotide binding protein β subunit-like protein 12.3 (aa 192–200), or a yeast protein UBC5 (61–68), are among these candidate epitopes. HLA-B*5101 is the major subtype of HLA-B51 associated with BD and differs from HLA-B*5201, a split antigen of B5 but unlinked to BD, by only two amino acids at positions 63 and 67 which are in pocket B, the antigen-binding groove. These amino acids are possibly crucial anchor residues for peptide binding. Similarly, B*5102 differs from B*5102 and *5103 only at positions 171 and 167, respectively. However, *5102 and *5103 are very rare alleles and whether they are not associated with BD only because of their low frequency is unknown. With this current knowledge, a candidate “Behçetogenic” epitope presented by *5101 is described as DAIXXXXXF, a hypothetical disease inducing peptide.62 The *B5108 and *5109 subtypes have also been detected in patients with BD recently, and their sequence analysis should also be explored and compared with that of *5101.63

The role of HLA-B51-specific peptides and whether HLA-B51 restricted CD8+ T cells have a role in the cause of BD is currently unknown.64 As described above, HLA-B51 transgenic mice have an enhanced activation of neutrophils. Possibly, HLA-B51 may present an endogenous antigen to cytotoxic T cells in B51 transgenic mice and activate the cytokine cascade, causing superoxide release from neutrophils without a primary defect.64

Similarities between BD and Takayasu's arteritis also merit attention as this granulomatous, rare vasculitis, present in some countries such as Japan with a high prevalence of BD, is strongly associated with HLA-B*5201.64 Possible differences in binding peptides owing to two amino acid changes of HLA-B*5201 and *5101 seem to cause a very different clinical spectrum in the same geographical setting.

Another gene positioned close to B51 and found on the same haplotype may also be implicated in BD. Mizuki and Ohno first reported an association of MICA (MHC class I related gene) between the TNFα gene and the HLA-B region on chromosome 6, with BD.64 Although, associations of BD with triplet repeat microsatellite polymorphisms in the transmembrane region of the MICA gene, alleles A6 and A9, were also found in other studies, a strong linkage disequilibrium of MICA with HLA-B51 and its low heterogeneity make MICA an unlikely candidate as a major BD gene.65 However, MICA may still be a second gene relevant to BD as it has been shown to stimulate γδ T and NK cells.66 MICA is expressed mainly by endothelial cells and fibroblasts, but not by monocytes and keratinocytes, and endothelial expression of MICA may be a target antigen of antiendothelial responses such as graft rejection.66 Similarly, endothelial injury in BD may also be perpetuated by anti-MICA responses.

Retinal-S antigen and HLA-B51—new autoantigens?

Another candidate autoantigen in BD is retinal-S antigen (S-Ag). This protein is found mainly in the retina and is possibly immune-privileged, with immune responses only seen after tissue destruction owing to uveitis. T cell responses against S-Ag are present in various types of human uveitis, including BD.66,67 Among the immunodominant epitopes of S-Ag, an epitope (aa 342–355, PDS-Ag) is found to share homology with a conserved region of HLA-B molecules (aa 125–138, B27PD) such as B51 and B27, which are linked to uveitis in BD and spondyloarthropathies.68 As this epitope is presented to and recognised by CD4+ T cells, a model in which class I HLA molecules become antigenic epitopes themselves is proposed.62 According to this model, HLA derived peptides are prominent in selecting the repertoire of CD4+ T cell reactivity and, as a consequence, in defining susceptibility to some autoimmune diseases. Indeed, a significant portion of small peptides eluded from the surface of various HLA class II molecules are found to originate from HLA class I, including B27PD.71 As T cells recognising class I antigens are a natural part of our immune repertoire, but possibly tolerised in thymus, a breakdown of tolerance may occur after uveal inflammation by cross reactivity of PDS-Ag and B27PD reactive T cells (fig 2). Increased proinflammatory cytokine and chemokines in patients with uveitis may also enhance class I HLA molecule expression on cell surfaces, increasing their

An infectious trigger (Streptococci, HSP65) → Acute anterior uveitis → No retinal damage → Retinal damage → REMISSION

<table>
<thead>
<tr>
<th>HLA expression</th>
<th>S-Ag reactive CD4+ T cells</th>
<th>HLA-B27/S1 reactive CD4+ T cells</th>
<th>Proinflammatory and Th1 cytokine release</th>
</tr>
</thead>
</table>

**Figure 2** An immunological model for the role of cross reactive retinal-S antigen (S-Ag) and HLA-B27/S1 derived peptides in chronic posterior uveitis of Behçet’s disease.
intracellular turnover and immune presentation. Development of uveitis in rats by both peptides is supportive of this model. T cell responses to these uveitogenic peptides were first shown in German patients with uveitis, and recently confirmed in a larger group of patients with BD from Turkey. Interestingly, only T cells from patients with posterior uveitis but not from the HLA-B51+ BD group without uveitis are responsive to uveitogenic peptides. This suggests that serious uvea destruction and activation of PDS-Ag reactive T cells is required for cross reactive anti-B27PD responses. Increased IL2 and TNFα releases are also present after PDS-Ag and B27PD stimulation of peripheral blood mononuclear cells, with a proinflammatory, Th1 type of immune response. Oral feeding of B27PD derived peptide prevents S-Ag uveitis in the animal model, and has now been tried in patients with refractory uveitis as a means of “oral tolerance” treatment. 

**Vascular disease and AECA**

Vascular involvement in BD is predominantly venous in contrast with systemic vasculitides. However, the rare presence of pulmonary emboli is suggestive of “sticky” thrombi, and in histopathological studies, in addition to thrombi, inflammatory infiltrates in vessel walls point to a vasculitic process. Vasculitis is also commonly present in the histopathological specimens of oral and genital ulcers, erythema nodosum-like lesions, epidemicymitis, enteritis, and central nervous system lesions of BD. Non-lytic antibodies against endothelial cells are commonly present in both vascular and non-vascular BD. A 44 kDa endothelial antigen is recognised by IgM AECAs of patients with BD. These antibodies increase the expression of ICAM-1 on endothelial cells and can activate the mitogen activated protein cascade through the extracellular signal regulated kinase. Increased factor V Leiden and the prothrombin gene G20210A mutations, mainly in patients with venous thrombosis and retinal occlusive disease, also show the role of increased propensity to thrombosis. Endothelium dependent, brachial artery flow mediated dilatation is also impaired in BD, which is improved by vitamin C treatment and suggests a role for oxidative stress in vascular involvement.

**Severity and sex**

One currently underexplored area is differences between the sexes in BD, which is more severe in men. Severe complications, such as vascular, central nervous system, and pulmonary disease, as well as mortality, are related to the male sex. However, serum levels of testosterone and oestradiol are not different in male patients with BD. Sebum excretion rates are under androgenic control are increased in BD, but also in patients with RA. Oestrogen is shown to protect against endotoxin induced uveitis in Lewis rats. In endotoxin induced uveitis, cellular infiltration is more marked in male than in female rats, and ovariectomy increases cellular infiltration. Oestrogen decreases E-selectin and IL6 gene expressions through oestrogen receptors in the vascular endothelium. As another mechanism, FMLP stimulated superoxide generation from neutrophils is decreased in vitro with oestrogen incubation. Through these mechanisms, oestrogen may suppress the proinflammatory functions of vascular endothelium and neutrophils, explaining the milder clinical course in women.

**Behçet’s syndrome: observations from the clinic. Different antigenic stimuli for different manifestations?**

The name “Behçet’s syndrome rather than Behçet’s disease” is suggested by Ehrlich et al owing to a different, milder clinical course in Western populations than in patients with the classical course from the “silk route”. Although this approach has not been universally agreed, it might be helpful in elucidating the predisposing genetic and environmental factors. Various manifestations of BD occurring unpredictably during the disease course and not linked to any previous risk factor may be associated with different organ-specific antigens or genetic predispositions. Therapeutic trials provide interesting clues, as the effects of various popular treatments in BD seem to be organ-specific. Colchicine is especially effective for erythema nodosum-like lesions but has a limited effect on arthritis or uveitis. It is not uncommon to see mucocutaneous lesions relapse in patients receiving immunosuppressive treatment which prevents ocular attacks. In a recent trial, thalidomide was found to be effective for oral and genital ulcers, but caused a significant increase in erythema nodosum lesions in the first eight weeks. As an explanation for this surprising observation, the authors suggested that “the cause of aphthous ulcers and erythema nodosum may not have a common putative denominator in BD”. Immune responses to local antigens, such as dermal keratins in psoriasis or synovial antigens such as collagen type II in rheumatoid arthritis, have been reported. Similarly, local, organ-specific antigens may be immunopathogenic for patient subgroups with mucocutaneous, ocular, or articular organ involvement in BD. Retinal S-antigen derived PDS-Ag, with T cell recognition, found only in patients with posterior uveitis, is a candidate organ-specific antigen of this type. Similarly, the presence of anti-HSP60 antibodies, mainly in patients with parenchymal neuro-BD, but not in pure vascular form, underlines the fact that even within the same organ immune responses may reflect different clinical subtypes.

**Summary**

Both innate and adaptive immune systems are activated in BD, with a proinflammatory and Th1-type of cytokine profile. BD may be linked to a specific, primary immune abnormality with a genetic mutation affecting an adhesion molecule or a proinflammatory cytokine, which predisposes to early or more intense neutrophil and T cell responses. Alternatively, a broad
intracellular signalling abnormality of a trans-cription factor, which lowers the threshold of inflammatory responses to external stimuli, as proposed for familial Mediterranean fever with decrease in peroxisome proliferator expression of neutrophils, may be present (hyperreactivity model).

However, an adaptive immune system is also crucial in BD, with possibly both external (streptococal, microbial) and internal (heat shock or organ-specific proteins) antigens driving the pathogenic tissue T cell infiltrations. Better characterisation of pathogenic immune cell subsets, systemic and local antigens, and abnormal cell-activation mechanisms may help in the future to develop more specific and less toxic immunotherapeutic approaches to the still unsatisfactorily treated BD.

The author thanks Professor H Yaziçi for critically reading the manuscript.

The studies by the author and his collaborators are supported by grants from Turkish Scientific and Technical Council (TÜBİTAK).

6 Suzuki Y, Hoshi K, Matsuda T, Mizushima Y. Increased serum levels of Th2 cytokines IL-4 and IL-10 in Behçet’s disease. J Rheumatol 1999;26:826–32.
17 Topalan E, Buyukarslan A, Orozco A, Yurtseven O, Yilmaz I, Yilmaz N. Increased intracellular signalling abnormality of a transcription factor which lowers the threshold of inflammatory responses to external stimuli, as proposed for familial Mediterranean fever with decrease in peroxisome proliferator expression of neutrophils, may be present (hyperreactivity model).
18 The studies by the author and his collaborators are supported by grants from Turkish Scientific and Technical Council (TÜBİTAK).


